NEW YORK (TheStreet) -- CHANGE IN RATINGSCA ( CA) was downgraded from buy to neutral at Mizuho. $25 price target. CEO could change the product development process, which might cause near-term disruptions, Mizuho said. F5 Networks ( FFIV) was downgraded to hold at TheStreet Ratings. First Niagara ( FNFG) was upgraded to outperform at KBW. $10.50 price target. New CEO could prove to be an inflection point for the company, Keefe, Bruyette & Woods said. Johnson & Johnson ( JNJ) was downgraded to neutral from overweight at J.P. Morgan. $83 price target. Valuation call. Juniper Networks ( JNPR) was upgraded at Argus to buy from hold. $22 price target. Earnings recovery is finally underway, Argus said.
L-3 Communications ( LLL) was downgraded at J.P. Morgan to underweight from neutral. Company is most at risk from sequestration cuts, J.P. Morgan said. Vail Resorts ( MTN) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Valuation call, as the stock is up 44% over the past year, Credit Suisse said. Northrop Grumman ( NOC) was upgraded at J.P. Morgan to equal-weight from underweight. Valuation call, J.P. Morgan said. Public Service ( PEG) was downgraded at Argus to hold from buy. Valuation call, as the stock is approaching the previous $35 price target, Argus said.
RDA Microelectronics ( RDA) was downgraded to hold at TheStreet Ratings. Vertex Pharmaceuticals ( VRTX) was initiated with a hold rating at Canaccord. Valuation call, based on a $55 price target. Whiting Petroleum ( WLL) was upgraded to overweight at J.P. Morgan. Valuation call, given the company's better outlook, J.P. Morgan said. STOCK COMMENTS/EPS CHANGES Apple ( AAPL) estimates were increased at Canaccord Genuity through 2014. Company is seeing higher iPhone 4 and 4S sales, and new products should continue to drive demand. Buy rating and $600 price target. AstraZeneca ( AZN) estimates were cut at Leerink Swann through 2014. Cautious feedback for Fostamatinib lowers the chance for FDA approval, Leerink Swann said. Daimler ( DDAIF) price target and estimates were reduced at UBS. First-quarter guidance was worse than expected on weak markets (Germany) and wholesale sales, driving a reduction in earnings estimates, said UBS. The price target goes to $70.22. Hanesbrands ( HBI) price target and estimates were increased at Citigroup. The price target was increased to $54 after the company initiated a dividend which will attract new investors, said Citigroup. Earnings estimates for 2013 were increased given a better-than-expected first quarter result, Citigroup added.